10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

HSP70 Polyclonal Antibody

Catalog # AP73607

Product Information


Application	IF, ICC, WB, IHC-P, E
Primary Accession	P08107
Reactivity	Human, Rat, Mouse
Host	Rabbit
Clonality	Polyclonal

Additional Information


Other Names	HSPA1A; HSPA1; HSPA1B; Heat shock 70 kDa protein 1A/1B; Heat shock 70 kDa protein 1/2; HSP70-1/HSP70-2; HSP70.1/HSP70.2
Dilution	IF~~IF: 1:50-200 Western Blot: 1/500 - 1/2000. IHC-p: 1/100-1/300. ELISA: 1/20000. Not yet tested in other applications. ICC~~N/A WB~~IF: 1:50-200 Western Blot: 1/500 - 1/2000. IHC-p: 1/100-1/300. ELISA: 1/20000. Not yet tested in other applications. IHC-P~~IF: 1:50-200 Western Blot: 1/500 - 1/2000. IHC-p: 1/100-1/300. ELISA: 1/20000. Not yet tested in other applications. E~~N/A
Format	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.
Storage Conditions	-20℃

Protein Information


Images




Immunofluorescence analysis of human-kidney tissue. 1,HSP70 Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of human-kidney tissue. 1,HSP70 Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Western Blot analysis of MCF7 cells using HSP70 Polyclonal Antibody.. Secondary antibody was diluted at 1:20000



Immunohistochemical analysis of paraffin-embedded human-Breast-cancer, antibody was diluted at 1:100



Immunohistochemical analysis of paraffin-embedded human-Breast-cancer, antibody was diluted at 1:100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.